The current status of metabolomics in drug discovery and development

Drug Development Research

Volumn 73, Issue 8, 2012, Pages 535-546

  Robertson, Donald G ^a   Reily, Michael D ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

drug discovery; metabolomics

Indexed keywords

BIOLOGICAL MARKER; EDETIC ACID; HEPARIN; LYSOPHOSPHOLIPID; PARACETAMOL;

DRUG DEVELOPMENT; DRUG EFFICACY; DRUG INDUSTRY; DRUG SAFETY; HUMAN; LIVER TOXICITY; MASS SPECTROMETRY; METABOLOMICS; MOLECULAR DYNAMICS; MOLECULAR WEIGHT; NONALCOHOLIC FATTY LIVER; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; REVIEW; TRANSLATIONAL RESEARCH;

EID: 84870936588     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.21047     Document Type: Review

References (69)

1. Aranibar N, Vassallo JD, Rathmacher J, Stryker S, Zhang Y, Dai J, Janovitz EB, Robertson D, Reily M, Lowe-Krentz L, et al. 2011. Identification of 1- and 3-methylhistidine as biomarkers of skeletal muscle toxicity by nuclear magnetic resonance-based metabolic profiling. Anal Biochem 410: 84-91.
2. Atherton HJ, Bailey NJ, Zhang W, Taylor J, Major H, Shockcor J, Clarke K, Griffin JL,. 2006. A combined 1H NMR spectroscopy and mass spectrometry-based metabolomic study of the PPAR-{alpha} null mutant mouse defines profound systemic changes in metabolism linked to the metabolic syndrome. Physiol Genomics 27: 178-186.
3. Backshall A, Alferez D, Teichert F, Wilson ID, Wilkinson RW, Goodlad RA, Keun HC,. 2009. Detection of metabolic alterations in non-tumor gastrointestinal tissue of the Apc(Min/+) mouse by (1)H MAS NMR spectroscopy. J Proteome Res 8: 1423-1430.
4. Bales JR, Higham DP, Howe I, Nicholson JK, Sadler PJ,. 1984. Use of high-resolution proton nuclear magnetic resonance spectroscopy for rapid multi-component analysis of urine. Clin Chem 30: 426-432.
5. Cho JY, Kang DW, Ma X, Ahn SH, Krausz KW, Luecke H, Idle JR, Gonzalez FJ,. 2009. Metabolomics reveals a novel vitamin E metabolite and attenuated vitamin E metabolism upon PXR activation. J Lipid Res 50: 924-937.
6. Cho JY, Matsubara T, Kang DW, Ahn SH, Krausz KW, Idle JR, Luecke H, Gonzalez FJ,. 2010. Urinary metabolomics in Fxr-null mice reveals activated adaptive metabolic pathways upon bile acid challenge. J Lipid Res 51: 1063-1074.
7. Chylla RA, Hu K, Ellinger JJ, Markley JL,. 2011. Deconvolution of two-dimensional NMR spectra by fast maximum likelihood reconstruction: application to quantitative metabolomics. Anal Chem 83: 4871-4880.
8. Clarke J, Novak P, Lake AD, Shipkova P, Aranibar N, Robertson D, Reily M, Lehman-McKeeman L, Cherrington NJ,. 2012. Characterization of hepatocellular carcinoma-related genes and metabolites in human nonalcoholic fatty liver disease. Toxicol Sci 126: 429.
9. Claudino WM, Quattrone A, Biganzoli L, Pestrin M, Bertini I, Di Leo A,. 2007. Metabolomics: available results, current research projects in breast cancer, and future applications. J Clin Oncol 25: 2840-2846.
10. Clayton TA, Lindon JC, Cloarec O, Antti H, Charuel C, Hanton G, Provost JP, Le Net JL, Baker D, Walley RJ, et al. 2006. Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature 440: 1073-1077.
11. Dunckley T, Coon KD, Stephan DA,. 2005. Discovery and development of biomarkers of neurological disease. Drug Discov Today 10: 326-334.
12. Dunn WB, Broadhurst DI, Atherton HJ, Goodacre R, Griffin JL,. 2011. Systems level studies of mammalian metabolomes: the roles of mass spectrometry and nuclear magnetic resonance spectroscopy. Chem Soc Rev 40: 387-426.
13. Ebbels TM, Keun HC, Beckonert OP, Bollard ME, Lindon JC, Holmes E, Nicholson JK,. 2007. Prediction and classification of drug toxicity using probabilistic modeling of temporal metabolic data: the consortium on metabonomic toxicology screening approach. J Proteome Res 6: 4407-4422.
14. Fiehn O,. 2001. Combining genomics, metabolome analysis, and biochemical modeling to understand metabolic networks. Comp Funct Genomics 2: 155-168.
15. Gall WE, Beebe K, Lawton KA, Adam KP, Mitchell MW, Nakhle PJ, Ryals JA, Milburn MV, Nannipieri M, Camastra S, et al. 2010. alpha-hydroxybutyrate is an early biomarker of insulin resistance and glucose intolerance in a nondiabetic population. PLoS ONE 5: e10883.
16. Griffin JL, Cemal CK, Pook MA,. 2004. Defining a metabolic phenotype in the brain of a transgenic mouse model of spinocerebellar ataxia 3. Physiol Genomics 16: 334-340.
17. Hnatyshyn S, Shipkova P,. 2012. Automated and unbiased analysis of LC-MS metabolomic data. Bioanalysis 4: 541-554.
18. Keun HC, Ebbels TMD, Antti H, Bollard ME, Beckonert O, Schlotterbeck G, Senn H, Niederhauser U, Holmes E, Lindon JC, et al. 2002. Analytical reproducibility in 1H NMR-based metabonomic urinalysis. Chem Res Toxicol 15: 1380-1386.
19. Laferrere B, Reilly D, Arias S, Swerdlow N, Gorroochurn P, Bawa B, Bose M, Teixeira J, Stevens RD, Wenner BR, et al. 2011. Differential metabolic impact of gastric bypass surgery versus dietary intervention in obese diabetic subjects despite identical weight loss. Sci Transl Med 3 (80): 80re2.
20. Leo GC, Darrow AL,. 2009. NMR-based metabolomics of urine for the atherosclerotic mouse model using apolipoprotein-E deficient mice. Magn Reson Chem 47 (Suppl 1): S20-S25.
21. Lin HM, Edmunds SI, Helsby NA, Ferguson LR, Rowan DD,. 2009. Nontargeted urinary metabolite profiling of a mouse model of Crohn's disease. J Proteome Res 8: 2045-2057.
22. Lindon JC, Holmes E, Bollard ME, Stanley EG, Nicholson JK,. 2004a. Metabonomics technologies and their applications in physiological monitoring, drug safety assessment and disease diagnosis. Biomarkers 9: 1-31.
23. Lindon JC, Holmes E, Nicholson JK,. 2004b. Metabonomics: systems biology in pharmaceutical research and development. Curr Opin Mol Ther 6: 265-272.
24. Lindon JC, Holmes E, Nicholson JK,. 2006. Metabonomics techniques and applications to pharmaceutical research & development. Pharm Res 23: 1075-1088.
25. Lindon JC, Keun HC, Ebbels TM, Pearce JM, Holmes E, Nicholson JK,. 2005. The Consortium for Metabonomic Toxicology (COMET): aims, activities and achievements. Pharmacogenomics 6: 691-699.
26. Lindon JC, Nicholson JK,. 2008. Spectroscopic and statistical techniques for information recovery in metabonomics and metabolomics. Annu Rev Analyt Chem 1: 45-69.
27. Lindon JC, Nicholson JK, Everett JR,. 1999. NMR spectroscopy of biofluids. Annu Rep NMR Spectrosc 38: 1-88.
28. Lloyd DJ, Wheeler MC, Gekakis N,. 2010. A point mutation in Sec61alpha1 leads to diabetes and hepatosteatosis in mice. Diabetes 59: 460-470.
29. Makowski L, Noland RC, Koves TR, Xing W, Ilkayeva OR, Muehlbauer MJ, Stevens RD, Muoio DM,. 2009. Metabolic profiling of PPARalpha-/- mice reveals defects in carnitine and amino acid homeostasis that are partially reversed by oral carnitine supplementation. FASEB J 23: 586-604.
30. Martin FP, Rezzi S, Philippe D, Tornier L, Messlik A, Holzlwimmer G, Baur P, Quintanilla-Fend L, Loh G, Blaut M, et al. 2009. Metabolic assessment of gradual development of moderate experimental colitis in IL-10 deficient mice. J Proteome Res 8: 2376-2387.
31. Mayr M, Metzler B, Chung YL, McGregor E, Mayr U, Troy H, Hu Y, Leitges M, Pachinger O, Griffiths JR, et al. 2004. Ischemic preconditioning exaggerates cardiac damage in PKC-delta null mice. Am J Physiol Heart Circ Physiol 287: H946-H956.
32. Mayr M, Zampetaki A, Sidibe A, Mayr U, Yin X, De Souza AI, Chung YL, Madhu B, Quax PH, Hu Y, et al. 2008. Proteomic and metabolomic analysis of smooth muscle cells derived from the arterial media and adventitial progenitors of apolipoprotein E-deficient mice. Circ Res 102: 1046-1056.
33. Mishur RJ, Rea SL,. 2012. Applications of mass spectrometry to metabolomics and metabonomics: detection of biomarkers of aging and of age-related diseases. Mass Spectrom Rev 31: 70-95.
34. Murdoch TB, Fu H, MacFarlane S, Sydora BC, Fedorak RN, Slupsky CM,. 2008. Urinary metabolic profiles of inflammatory bowel disease in interleukin-10 gene-deficient mice. Anal Chem 80: 5524-5531.
35. Mutch DM, O'Maille G, Wikoff WR, Wiedmer T, Sims PJ, Siuzdak G,. 2007. Mobilization of pro-inflammatory lipids in obese Plscr3-deficient mice. Genome Biol 8: R38.
36. Newgard CB, An J, Bain JR, Muehlbauer MJ, Stevens RD, Lien LF, Haqq AM, Shah SH, Arlotto M, Slentz CA, et al. 2009. A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab 9: 311-326.
37. Nicholson JK, Buckingham MJ, Sadler PJ,. 1983. High resolution proton NMR studies of vertebrate blood and plasma. Biochem J 211: 605-615.
38. Nicholson JK, Connelly J, Lindon JC, Holmes E,. 2002. Metabonomics: a platform for studying drug toxicity and gene function. Nat Rev Drug Discov 1: 153-161.
39. Oresic M,. 2010. Systems biology strategy to study lipotoxicity and the metabolic syndrome. Biochim Biophys Acta 1801: 235-239.
40. Pears MR, Cooper JD, Mitchison HM, Mortishire-Smith RJ, Pearce DA, Griffin JL,. 2005. High resolution 1H NMR-based metabolomics indicates a neurotransmitter cycling deficit in cerebral tissue from a mouse model of batten disease. J Biol Chem 280: 42508-42514.
41. Pendyala G, Want EJ, Webb W, Siuzdak G, Fox HS,. 2007. Biomarkers for neuroAIDS: the widening scope of metabolomics. J Neuroimmune Pharmacol 2: 72-80.
42. Quinones MP, Kaddurah-Daouk R,. 2009. Metabolomics tools for identifying biomarkers for neuropsychiatric diseases. Neurobiol Dis 35: 165-176.
43. Reily MD, Shipkova P, Hnatyshyn S,. 2011. LC-MS in endogenous metabolite profiling and small molecule biomarker discovery. In:, Lee MS, Zhu M, editors. Mass spectrometry in drug metabolism and disposition: basic principles and applications. Hoboken, NJ: John Wiley & Sons, p 685-722.
44. Reily MD, Lindon JC,. 2005. NMR spectroscopy: principles and instrumentation. In:, D.G Robertson JCL, Holmes E, Nicholson JK, editors. Metabonomics in toxicity assessment. New York and Boca Raton, FL: Taylor & Francis, p 75-104.
45. Reily MD, Robosky LC, Manning ML, Butler A, Baker JD, Winters RT,. 2006. DFTMP, an NMR reagent for assessing the near-neutral pH of biological samples. J Am Chem Soc 128: 12360-12361.
46. Robertson DG,. 2005. Metabonomics in toxicology: a review. Toxicol Sci 85: 809-822.
47. Robertson DG, Reily MD, Baker JD,. 2005. Metabonomics in preclinical drug development. Expert Opin Drug Metab Toxicol 1: 363-376.
48. Robertson DG, Reily MD, Sigler RE, Wells DF, Paterson DA, Braden TK,. 2000. Metabonomics: evaluation of nuclear magnetic resonance (NMR) and pattern recognition technology for rapid in vivo screening of liver and kidney toxicants. Toxicol Sci 57: 326-337.
49. Robertson DG, Watkins PB, Reily MD,. 2011. Metabolomics in toxicology: preclinical and clinical applications. Toxicol Sci 120 (Suppl 1): S146-S170.
50. Robosky LC, Robertson DG, Baker JD, Rane S, Reily MD,. 2002. In vivo toxicity screening programs using metabonomics. Comb Chem High Throughput Screen 5: 651-662.
51. Salek RM, Xia J, Innes A, Sweatman BC, Adalbert R, Randle S, McGowan E, Emson PC, Griffin JL,. 2010. A metabolomic study of the CRND8 transgenic mouse model of Alzheimer's disease. Neurochem Int 56: 937-947.
52. Smith CA, O'Maille G, Want EJ, Qin C, Trauger SA, Brandon TR, Custodio DE, Abagyan R, Siuzdak G,. 2005. METLIN: a metabolite mass spectral database. Ther Drug Monit 27: 747-751.
53. Stewart JD, Bolt HM,. 2011. Metabolomics: biomarkers of disease and drug toxicity. Arch Toxicol 85: 3-4.
54. Suhre K, Meisinger C, Doring A, Altmaier E, Belcredi P, Gieger C, Chang D, Milburn MV, Gall WE, Weinberger KM, et al. 2010. Metabolic footprint of diabetes: a multiplatform metabolomics study in an epidemiological setting. PLoS ONE 5: e13953.
55. Teichert F, Verschoyle RD, Greaves P, Edwards RE, Teahan O, Jones DJ, Wilson ID, Farmer PB, Steward WP, Gant TW, et al. 2008. Metabolic profiling of transgenic adenocarcinoma of mouse prostate (TRAMP) tissue by 1H-NMR analysis: evidence for unusual phospholipid metabolism. Prostate 68: 1035-1047.
56. Theodoridis G, Gika HG, Wilson ID,. 2011. Mass spectrometry-based holistic analytical approaches for metabolite profiling in systems biology studies. Mass Spectrom Rev 30: 884-906.
57. Tsang TM, Woodman B, McLoughlin GA, Griffin JL, Tabrizi SJ, Bates GP, Holmes E,. 2006. Metabolic characterization of the R6/2 transgenic mouse model of Huntington's disease by high-resolution MAS 1H NMR spectroscopy. J Proteome Res 5: 483-492.
58. Underwood BR, Broadhurst D, Dunn WB, Ellis DI, Michell AW, Vacher C, Mosedale DE, Kell DB, Barker RA, Grainger DJ, et al. 2006. Huntington disease patients and transgenic mice have similar pro-catabolic serum metabolite profiles. Brain 129 (Pt 4): 877-886.
59. van der Greef J, van der Heijden R, Verheij ER,. 2004. The role of mass spectrometry in systems biology: data processing and identification strategies in metabolomics. Adv Mass Spectrom 16: 145-165.
60. Vasan RS,. 2006. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation 113: 2335-2362.
61. Vinaixa M, Rodriguez MA, Rull A, Beltran R, Blade C, Brezmes J, Canellas N, Joven J, Correig X,. 2010. Metabolomic assessment of the effect of dietary cholesterol in the progressive development of fatty liver disease. J Proteome Res 9: 2527-2538.
62. Wang TJ, Larson MG, Vasan RS, Cheng S, Rhee EP, McCabe E, Lewis GD, Fox CS, Jacques PF, Fernandez C, et al. 2011. Metabolite profiles and the risk of developing diabetes. Nat Med 17: 448-453.
63. Want EJ, Nordström A, Morita H, Siuzdak G,. 2007. From exogenous to endogenous: the inevitable imprint of mass spectrometry in metabolomics. J Proteome Res 6: 459-468.
64. Warrack BM, Hnatyshyn S, Ott KH, Reily MD, Sanders M, Zhang H, Drexler DM,. 2009. Normalization strategies for metabonomic analysis of urine samples. J Chromatogr B Analyt Technol Biomed Life Sci 877: 547-552.
65. Waterfield CJ, Jairath M, Asker DS, Timbrell JA,. 1995. The biochemical effects of clenbuterol: with particular reference to taurine and muscle damage. Eur J Pharmacol 293: 141-149.
66. Winnike JH, Li Z, Wright FA, Macdonald J, O'Connell TM, Watkins PB,. 2010. Use of pharmaco-metabonomics for early prediction of acetaminophen-induced hepatotoxicity in humans. Clin Pharmacol Ther 88: 45-51.
67. Wishart DS,. 2011. Advances in metabolite identification. Bioanalysis 3: 1769-1782.
68. Young VR, Havenberg LN, Bilmazes C, Munro HN,. 1973. Potential use of 3-methylhistidine excretion as an index of progressive reduction in muscle protein catabolism during starvation. Metabolism 23: 1429-1436.
69. Zhen Y, Krausz KW, Chen C, Idle JR, Gonzalez FJ,. 2007. Metabolomic and genetic analysis of biomarkers for peroxisome proliferator-activated receptor alpha expression and activation. Mol Endocrinol 21: 2136-2151.